Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Blood advances - 11 Feb 2020

Tarver Theodore C, Hill Jason E, Rahmat Leena, Perl Alexander E, Bahceci Erkut, Mori Kenichi, Smith Catherine C

Abstract excerpt

Gilteritinib is the first FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitor (TKI) approved as monotherapy in acute myeloid leukemia with FLT3 internal tandem duplication and D835/I836 tyrosine kinase domain (TKD) mutations. Sequencing studies in patients have uncovered less common, noncanonical (NC) mutations in FLT3 and have implicated secondary TKD mutations in FLT3 TKI resistance. We report that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chronic Lymphocytic Leukemia Research

Share to Chronic Myeloid Leukemia Treatments

Share to fms-Like Tyrosine Kinase 3

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyrazines

Source

Open in PubMed Open full text

Identifiers

PMID: 32040554
DOI: 10.1182/bloodadvances.2019000919
PMCID: PMC7013266

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.PMID 32040554Read ↗

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistanceSemantic proximity Read ↗

Gilteritinib: potent targeting of FLT3 mutations in AML.Semantic proximity Read ↗

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.Semantic proximity Read ↗

An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L.Semantic proximity Read ↗

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.Semantic proximity Read ↗

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid LeukemiaSemantic proximity Read ↗

The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinibSemantic proximity Read ↗

FLT3 Inhibition in Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging ControversiesSemantic proximity Read ↗

FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.Semantic proximity Read ↗

The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.Semantic proximity Read ↗

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.